Thursday, May 21, 2026
← Back to archivePolicy
Policy•Fierce Pharma•May 21, 2026
Ipsen details growing pains as teens transition to adult care
background ▾
- •Ipsen-commissioned survey documents widespread problems in pediatric-to-adult care transitions, a longstanding healthcare system challenge
Ipsen
→ Read original articlePolicy•Fierce Pharma•May 21, 2026
Amgen, bidding adieu to CFO, lures Galderma exec with hefty $12.4M bonus
background ▾
- •Amgen CFO departure signals leadership transition; replacement sourced from Galderma at substantial recruitment cost
AmgenGalderma
→ Read original articlePolicy•Fierce Pharma•May 21, 2026
CG Life appoints Collette Douaihy as chief creative officer as C-suite buildout continues
background ▾
- •CG Life continues C-suite buildout with appointment of experienced healthcare marketing executive
CG LifeDentsu InternationalEvoke
→ Read original articlePolicy•STAT News•May 21, 2026
Opinion: STAT+: Dark times ahead at the FDA
background ▾
- •Three key FDA leadership positions (Commissioner, CDER Director, CBER Acting Director) simultaneously vacant with only acting leadership, creating unprecedented regulatory uncertainty
- •Industry perceives these removals as an ideological purge rather than routine personnel changes, signaling potential shifts in FDA drug review philosophy and standards
- •Leadership instability at CBER is particularly concerning given its revolving-door history; implications for gene/cell therapy and biologics approval pathways require close monitoring
Policy•STAT News•May 21, 2026
Are ‘AI co-scientist’ tools actually useful for scientists?
background ▾
- •AI co-scientist tools remain largely dependent on human direction to define problems, constrain search spaces, and validate results—they do not autonomously conduct science
- •Active scientists report that hypothesis generation is not their primary constraint; funding alignment and resource availability are the real bottlenecks limiting research progress
- •Both Google and FutureHouse systems exhibit reproducibility and factuality issues (variable results across runs, hallucinations) that undermine confidence in their reliability for rigorous scientific work
GoogleFutureHouseMedStar Health Research Institute
→ Read original articleMarket Access
Market Access•Fierce Biotech•May 20, 2026
GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm
background ▾
- •Merger creates $21B dedicated healthcare investment manager with enhanced Asia-Pacific penetration, addressing the region's 40% share of global healthcare R&D spend
- •Combined firm will leverage complementary geographic strengths to provide portfolio companies with expanded market access and capital connectivity across three major healthcare markets
Global Healthcare OpportunitiesCBC GroupAvid Bioservices
→ Read original articleMarket Access•Fierce Biotech•May 20, 2026
Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues
background ▾
- •Lilly has spent over $5.7 billion on acquisitions in recent months (Ajax $2.3B, Kelonia $3.2B, Engage $202M), signaling a deliberate strategy to deploy GLP-1 windfall into genetic therapies and cell therapy platforms
- •Engage's non-viral DNA delivery technology addresses a genuine unmet need in redosability and tolerability, but the company remains preclinical with no disclosed development timeline or indication focus
- •Watch for: clinical candidate selection from Engage's platform, partnership announcements leveraging Lilly's manufacturing scale, and whether this acquisition accelerates genetic medicine timelines or faces integration challenges with Lilly's existing programs
Eli LillyEngage Biologics
→ Read original articleMarket Access•Fierce Pharma•May 21, 2026
Gilead inks another deal with Korean API manufacturer Yuhan, this time worth $140M
background ▾
- •Gilead deepens supply chain relationship with Yuhan through a $140M API manufacturing agreement
Gilead SciencesYuhan
→ Read original articleMarket Access•Fierce Pharma•May 21, 2026
Tarsus taps John Cena for its latest Demodex blepharitis campaign
background ▾
- •Tarsus is investing in celebrity-driven consumer awareness marketing to address the stigma surrounding Demodex blepharitis and expand the addressable patient population
Tarsus Pharmaceuticals
→ Read original articleMarket Access•Fierce Pharma•May 21, 2026
BeOne kicks off ‘One Save Changes Everything’ campaign with Tim Howard
background ▾
- •BeOne Medicines launched a corporate branding campaign with celebrity spokesperson Tim Howard
BeOne Medicines
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•May 20, 2026
With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate
background ▾
- •Oorja Bio acquired ORJ-001 (formerly NP-201) from NIBEC under a deal with up to $435 million in milestone payments, representing a significant bet on an understudied mechanism in IPF
- •Phase 2 initiation planned for later in 2025 will be critical to validate whether β1 integrin activation can achieve the claimed disease modification and reversal in IPF patients
- •Watch for Phase 2 enrollment progress and interim efficacy signals, as well as competitive moves by Avalyn Pharma and Celea Therapeutics in the IPF space
Oorja BioWestlake BioPartnersNIBECORJ-001NP-201pirfenidone
→ Read original articleClinical Trials•Endpoints News•May 20, 2026
Pfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M
background ▾
- •PF-07872412 achieved higher geometric mean titers for serotype 3 versus Prevnar 20, suggesting improved immunogenicity in a key serotype
- •A 25-valent formulation would expand coverage beyond Prevnar 20's 20 serotypes, potentially addressing remaining disease burden
- •Watch for pivotal efficacy trial initiation and regulatory pathway discussions with FDA/EMA
PfizerRelay TherapeuticsPF-07872412Prevnar 20
→ Read original articleClinical Trials•Fierce Biotech•May 20, 2026
Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails
background ▾
- •Batoclimab phase 3 trials in TED failed to meet primary endpoint despite post-hoc analysis suggesting benefit from deeper IgG suppression, suggesting the dosing or study design strategy may have been flawed rather than the mechanism itself
- •IMVT-1402 preliminary RA data (72.7% ACR20 response) and upcoming POC readout in cutaneous lupus plus phase 2b in Graves' disease suggest Immunovant is pivoting to autoimmune indications with potentially stronger clinical signals
- •Watch for IMVT-1402 topline data in cutaneous lupus (H2 2024) and Graves' disease (2025) to assess whether second-generation FcRn inhibition can succeed where batoclimab failed; competitive landscape includes other FcRn programs in development by larger pharma
ImmunovantRoivantHanAllbatoclimabIMVT-1402Vyvgart
→ Read original article